The Phase 3 ANDROMEDA study supports the approval of a subcutaneous (SC) regimen for the treatment of Light Chain (AL) amyloidosis, a rare and incurable blood disorder. Janssen Pharmaceuticals has announced reimbursement for the Darzalex® ▼ (daratumumab) SC formulation in combination with other drugs for adults with newly diagnosed AL amyloidosis. This announcement follows EC approval based on positive results from the Phase 3 study. The study showed that patients receiving the SC regimen had a significantly higher haematologic complete response rate compared to those receiving a different treatment regimen. This new treatment option aims to improve quality of life for patients with AL amyloidosis.
Source link
Darzalex▼ (daratumumab) subcutaneous (SC) formulation approved for reimbursement in Ireland for newly diagnosed systemic light chain amyloidosis
